Header Logo

Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.

Hamadeh IS, Moore DC, Martin A, Karabinos A, Hill H, Ndiaye A, Robinson JD, Paul BA, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):470-475.

View in: PubMed